Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats

European Journal of Pharmacology

Volumn 645, Issue 1-3, 2010, Pages 119-126

  Rutten, Kris ^a   De Vry, Jean ^a   Bruckmann, Walter ^a   Tzschentke, Thomas M ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Behavioural pharmacology; Drug dependence and abuse; Nociceptin; Opiate; ORL1

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; 8 ACENAPHTHEN 1 YL PHENYL 1,3,8 TRIAZA SPIRO[4,5]DECAN 4 ONE; COCAINE; DEXAMPHETAMINE; DIAMORPHINE; HYDROCODONE; MORPHINE; NOCICEPTIN RECEPTOR AGONIST; OXYCODONE; TILIDINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; INSTRUMENTAL CONDITIONING; MALE; MOTIVATION; NEUROPHARMACOLOGY; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REWARD; TASK PERFORMANCE;

ANALGESICS, OPIOID; ANIMALS; BENZIMIDAZOLES; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CONDITIONING (PSYCHOLOGY); DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; IMIDAZOLES; INJECTIONS, INTRAPERITONEAL; MALE; MORPHINE DERIVATIVES; MOTIVATION; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID; REWARD; SPIRO COMPOUNDS;

EID: 77956186737     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.07.036     Document Type: Article

References (43)

1. Berthele A., Platzer S., Dworzak D., Schadrack J., Mahal B., Buttner A., Assmus H.P., Wurster K., Zieglgansberger W., Conrad B., Tolle T.R. [3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain. Neuroscience 2003, 121:629-640.
2. Chiou L.C., Liao Y.Y., Fan P.C., Kuo P.H., Wang C.H., Riemer C., Prinssen E.P. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr. Drug Targets 2007, 8:117-135.
3. Ciccocioppo R., Panocka I., Polidori C., Regoli D., Massi M. Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology (Berl) 1999, 141:220-224.
4. Ciccocioppo R., Angeletti S., Panocka I., Massi M. Nociceptin/orphanin FQ and drugs of abuse. Peptides 2000, 21:1071-1080.
5. Ciccocioppo R., Angeletti S., Sanna P.P., Weiss F., Massi M. Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur. J. Pharmacol. 2000, 404:153-159.
6. Ciccocioppo R., Economidou D., Fedeli A., Angeletti S., Weiss F., Heilig M., Massi M. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl) 2004, 172:170-178.
7. Devine D.P., Reinscheid R.K., Monsma F.J., Civelli O., Akil H. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res. 1996, 727:225-229.
8. Di Giannuario A., Pieretti S. Nociceptin differentially affects morphine-induced dopamine release from the nucleus accumbens and nucleus caudate in rats. Peptides 2000, 21:1125-1130.
9. Economidou D., Fedeli A., Fardon R.M., Weiss F., Massi M., Ciccocioppo R. Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats. Peptides 2006, 27:3299-3306.
10. Economidou D., Hansson A.C., Weiss F., Terasmaa A., Sommer W.H., Cippitelli A., Fedeli A., Martin-Fardon R., Massi M., Ciccocioppo R., Heilig M. Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol. Psychiatry 2008, 64:211-218.
11. Ichikawa D., Ozaki S., Azuma T., Nambu H., Kawamoto H., Iwasawa Y., Takeshima H., Ohta H. In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated. NeuroReport 2001, 12:1757-1761.
12. Jenck F., Wichmann J., Dautzenberg F.M., Moreau J.L., Ouagazzal A.M., Martin J.R., Lundstrom K., Cesura A.M., Poli S.M., Roever S., Kolczewski S., Adam G., Kilpatrick G. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:4938-4943.
13. Kawamoto H., Ozaki S., Itoh Y., Miyaji M., Arai S., Nakashima H., Kato T., Ohta H., Iwasawa Y. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R, 4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J. Med. Chem. 1999, 42:5061-5063.
14. Koob G.F. Neural mechanisms of drug reinforcement. Ann.N.Y.Acad.Sci. 1992, 654:171-191.
15. Kotlinska J., Wichmann J., Legowska A., Rolka K., Silberring J. Orphanin FQ/nociceptin but not Ro 65-6570 inhibits the expression of cocaine-induced conditioned place preference. Behav. Pharmacol. 2002, 13:229-235.
16. Kotlinska J., Rafalski P., Biala G., Dylag T., Rolka K., Silberring J. Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats. Eur. J. Pharmacol. 2003, 474:233-239.
17. Kuzmin A., Sandin J., Terenius L., Ogren S.O. Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J. Pharmacol. Exp. Ther. 2003, 304:310-318.
18. Kuzmin A., Kreek M.J., Bakalkin G., Liljequist S. The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology 2007, 32:902-910.
19. Lambert D.G. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat. Rev. Drug Discov. 2008, 7:694-710.
20. Le Pen G., Wichmann J., Moreau J.L., Jenck F. The orphanin receptor agonist RO 64-6198 does not induce place conditioning in rats. NeuroReport 2002, 13:451-454.
21. Lutfy K., Do T., Maidment N.T. Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats. Psychopharmacology (Berl) 2001, 154:1-7.
22. Marquez P., Nguyen A.T., Hamid A., Lutfy K. The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine. Neuropharmacology 2008, 54:564-568.
23. Marquez P., Nguyen A.T., Hamid A., Lutfy K. The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine. Neuropharmacology 2008, 54:564-568.
24. Murphy N.P., Maidment N.T. Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J. Neurochem. 1999, 73:179-186.
25. Murphy N.P., Ly H.T., Maidment N.T. Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience 1996, 75:1-4.
26. Murphy N.P., Lee Y., Maidment N.T. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res. 1999, 832:168-170.
27. Murphy N.P., Tan A.M., Lam H.A., Maidment N.T. Nociceptin/orphanin FQ modulation of rat midbrain dopamine neurons in primary culture. Neuroscience 2004, 127:929-940.
28. Olianas M.C., Dedoni S., Boi M., Onali P. Activation of nociceptin/orphanin FQ-NOP receptor system inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and dopamine D(1) receptor signaling in rat nucleus accumbens and dorsal striatum. J. Neurochem. 2008, 107:544-556.
29. Ozaki S., Kawamoto H., Itoh Y., Miyaji M., Azuma T., Ichikawa D., Nambu H., Iguchi T., Iwasawa Y., Ohta H. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur. J. Pharmacol. 2000, 402:45-53.
30. Rover S., Adam G., Cesura A.M., Galley G., Jenck F., Monsma F.J., Wichmann J., Dautzenberg F.M. High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor. J. Med. Chem. 2000, 43:1329-1338.
31. Rutten K., van der Kam E.L., De Vry J., Tzschentke T.M. Extinction of conditioned place preference as a more refined method to assess the rewarding efficacy of opioids. Behav. Pharmacol. 2009, 20(suppl 1):S78.
32. Sakoori K., Murphy N.P. Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology (Berl) 2004, 172:129-136.
33. Sakoori K., Murphy N.P. Endogenous nociceptin (orphanin FQ) suppresses basal hedonic state and acute reward responses to methamphetamine and ethanol, but facilitates chronic responses. Neuropsychopharmacology 2008, 33:877-891.
34. Sakoori K., Murphy N.P. Expression of morphine-conditioned place preference is more vulnerable than naloxone-conditioned place aversion to disruption by nociceptin in mice. Neurosci. Lett. 2008, 443:108-112.
35. Schlicker E., Morari M. Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system. Peptides 2000, 21:1023-1029.
36. Shoblock J.R., Wichmann J., Maidment N.T. The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference. Neuropharmacology 2005, 49:439-446.
37. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 1998, 56:613-672.
38. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 2007, 12:227-462.
39. Tzschentke T.M., Bruckmann W., Friderichs E. Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol. Neurosci. Lett. 2002, 329:25-28.
40. Wichmann J., Adam G., Rover S., Cesura A.M., Dautzenberg F.M., Jenck F. 8-acenaphthen-1-yl-1-phenyl-1, 3, 8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. Bioorg. Med. Chem. Lett. 1999, 9:2343-2348.
41. Wichmann J., Adam G., Rover S., Hennig M., Scalone M., Cesura A.M., Dautzenberg F.M., Jenck F. Synthesis of (1S, 3aS)-8-(2, 3, 3a, 4, 5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1, 3, 8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. Eur. J. Med. Chem. 2000, 35:839-851.
42. Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci. 2003, 73:663-678.
43. Zhao R.J., Woo R.S., Jeong M.S., Shin B.S., Kim D.G., Kim K.W. Orphanin FQ/nociceptin blocks methamphetamine place preference in rats. NeuroReport 2003, 14:2383-2385.